

Divisional of U.S.S.N. 09/433,486

"Porous Drug Matrices and Methods for Manufacture Thereof"

By: Julie Straub, Howard Bernstein, Donald E. Chickering, III,

Sarwat Khattak, and Greg Randall

Express Mail Label No.: EL 690 662 580 US

Date of Deposit: November 3, 2000

PRELIMINARY AMENDMENT

23. (Once amended) A method of delivering a drug to a patient in need thereof,

comprising

Sub C 4
a1
*D
B
S
B
E
S
H
D*
a2
*H
B
B
S*
a3

administering a therapeutically or prophylactically effective amount of the drug in a formulation comprising a porous matrix [formed of] which comprises a wetting agent and microparticles of the drug, wherein the microparticles have a mean diameter between about 0.1 and 5 μm and a total surface area greater than about $0.5 \text{ m}^2/\text{mL}$, and wherein the [dry] porous matrix [is in a dry powder form having] has a TAP density less than or equal to 1.0 g/mL and/or [having] has a total surface area of greater than or equal to $0.2 \text{ m}^2/\text{g}$ and is in the form of a dry powder.

25. (Once amended) The method of claim 24 wherein the parenteral route is selected from the group consisting of [intravenous] intravenous, intraarterial, intracardiac, intrathecal, intraosseous, intraarticular, intrasynovial, intracutaneous, subcutaneous, and intramuscular administration.

32. (Once amended) The method of claim 23 wherein the formulation is [a dry powder] suitable for pulmonary administration.

Please add the following new claims:

Sub C 4
cont

--33. The method of claim 23 wherein the dry powder form of the porous matrix has a TAP density less than or equal to 1.0 g/mL.--

--34. The method of claim 23 wherein the dry powder form of the porous matrix has a total surface area of greater than or equal to $0.2 \text{ m}^2/\text{g}$ --